期刊
DIABETES
卷 61, 期 9, 页码 2199-2204出版社
AMER DIABETES ASSOC
DOI: 10.2337/db12-0052
关键词
-
资金
- Amylin
- Takeda
- BMS
- Novo Nordisk
- Jansen
- Boehringer-Ingelheim
Sodium glucose cotransporter 2 (SGLT2) inhibition is a novel and promising treatment for diabetes under late-stage clinical development. It generally is accepted that SGLT2 mediates 90% of renal glucose reabsorption. However, SGLT2 inhibitors in clinical development inhibit only 30-50% of the filtered glucose load. Why are they unable to inhibit 90% of glucose reabsorption in humans? We will try to provide an explanation to this puzzle in this perspective analysis of the unique pharmacoldnetic and pharmacodynamic profiles of SGLT2 inhibitors in clinical trials and examine possible mechanisms and molecular properties that may be responsible. Diabetes 61:2199-2204, 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据